THE LATEST
Searching for a Solution: An SKC Feature
Al Jazeera America covered the story of Solving Kids’ Cancer’s co-founders, Scott Kennedy & John London, and why they created the organization. Listen in on their stories and the inspiration behind the making of Solving Kids’ Cancer.
An Interview with Dr. Giselle Sholler: Nifurtimox Phase 1 Clinical Trial
Solving Kids’ Cancer’s co-founder, John London, share the story of how he stumbled upon Nifurtimox as a treatment option for neuroblastoma and brought it to a Phase 1 clinical trial. Listen in as we interview Dr. Giselle Sholler as she speaks on her clinical trial that was one of the first trials SKC funded.
Challenging the Status Quo
“Solving Kids’ Cancer and the TDI offer the opportunity to develop a much more facile system for drug development.” – Dr. Kenneth Cohen from the Sidney Kimmel Cancer Center at John Hopkins University
Solving Kids’ Cancer Begins
Solving Kids’ Cancer is dedicated to facilitating the development of therapies to improve survivorship for children with fatal childhood cancers through an innovative and aggressively funded model. Meet the co-founders of Solving Kids’ Cancer, John London, and Scott Kennedy. Watch to learn about their stories and their inspirations to opening Solving Kids’ Cancer.
Clinical Trial Opens Using Natural Killer Cells
Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors. Solving Kids’ Cancer and The Catherine Elizabeth Blair Memorial Foundation awarded a $136,000 grant to support the novel immunotherapy clinical trial for childhood cancer.
Two Moms Raise More Than $20,000 for Children With Cancer
One hundred percent of all donations collected by these two moms will help fund a clinical trial for kids with relapsed neuroblastoma, a deadly childhood cancer. Children with relapsed or refractory neuroblastoma have few or little curative options today.
Muli’s Story: Finding a Clinical Trial
After doctors in Israel told Myriam there were no more treatment options left for her son, Muli, to treat his high-risk neuroblastoma, she searched for clinical trials outside of Israel. She found a vaccine trial In Hershey, Pa., sponsored by Solving Kids’ Cancer. In this video, Myriam tells her family’s story to save Muli.
New Experimental Immunotherapy for Children with High-Risk Solid Tumors using T-cells
Researchers at the Children`s Hospital of Philadelphia, the University of Pennsylvania, and the Primary Children`s Medical Center of Salt Lake City received a $550,000 collaborative grant to test next generation T-cell immunotherapy strategies in children with neuroblastoma, a solid tumor with poor prognosis that is responsible for 15% of all childhood cancer deaths.
Dendritic Cell Vaccine Trial Shows Promising Results
One year after his last treatment, a six-year-old boy with recurrent neuroblastoma is in complete remission for his high-risk metastatic cancer. Doctors reported this case study in the January 2013 issue of Pediatrics, the journal of the American Academy of Pediatrics.